X0609 4 2026-09-10 0001628171 Revolution Medicines, Inc. RVMD 0002124509 Mancini Anthony false REVOLUTION MEDICINES, INC. 700 SAGINAW DRIVE REDWOOD CITY CA 94063 false true false false See Remarks true Common Stock 2026-09-10 4 M false 9363 33.62 A 59338 D Common Stock 2026-09-10 4 S false 6019 203.2844 D 53319 D Common Stock 2026-09-10 4 S false 5530 204.1357 D 47789 D Common Stock 2026-09-10 4 S false 2420 205.0513 D 45369 D Common Stock 2026-09-10 4 S false 1179 206.0995 D 44190 D Common Stock 2026-09-10 4 S false 300 207.1733 D 43890 D Stock Option (Right to Buy) 33.62 2026-09-10 4 M false 9363 0 D 2035-03-31 Common Stock 9363 96746 D Transaction made pursuant to a 10b5-1 trading plan adopted by Anthony Mancini on June 11, 2026. The transaction was executed in multiple trades at prices ranging from $202.64 to $203.63, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. The transaction was executed in multiple trades at prices ranging from $203.64 to $204.63, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. The transaction was executed in multiple trades at prices ranging from $204.64 to $205.55, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. The transaction was executed in multiple trades at prices ranging from $205.85 to $206.70, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. The transaction was executed in multiple trades at prices ranging from $207.12 to $207.28, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Includes 43,700 restricted stock units. Twenty-five percent of the total shares subject to the option will vest on the first year anniversary measured from April 1, 2025 (the "Vesting Commencement Date") and one forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary of the Vesting Commencement Date thereafter, so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Chief Global Commercialization Officer /s/ Jack Anders, as Attorney-in-fact for Anthony Mancini 2026-09-14